HARMONY BIOSCIENCES HLDG INC (HRMY)
Health Care · NASDAQ
Harmony Biosciences is a neuroscience-focused biopharmaceutical company with a differentiated portfolio spanning sleep/wake disorders, rare epilepsy, and neurobehavioral conditions, anchored by WAKIX, the first-in-class non-scheduled narcolepsy treatment.
What HARMONY BIOSCIENCES HLDG INC does
Harmony Biosciences is a neuroscience-focused biopharmaceutical company developing and commercializing treatments for rare neurological diseases. The company's lead product, WAKIX (pitolisant), is a first-in-class H3 receptor antagonist approved for narcolepsy and excessive daytime sleepiness across multiple patient populations. Beyond narcolepsy, Harmony has expanded into rare epilepsy through the acquisition of Epygenix Therapeutics, developed next-generation pitolisant formulations, and recently entered orexin science and cell replacement therapy approaches through partnerships and collaborations.
Themes: ["Rare sleep/wake disorders – narcolepsy and excessive daytime sleepiness","Rare epilepsy – Dravet Syndrome, Lennox-Gastaut Syndrome, developmental and epileptic encephalopathies","Orphan drug development and commercialization","First-in-class therapeutics with novel mechanisms of action","Cell replacement therapy for neurological disorders","Non-scheduled controlled substance alternative for narcolepsy treatment"]
Fundamentals
- Price$38.21 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return+16.3% as of 2026-07-09 close
- P/E15.16 as of 2026-07-10
- Net margin+16.2% as of 2026-07-10
- Gross margin+76.5% as of 2026-07-10
- ROE+17.2% as of 2026-07-10
- Debt / equity0.17 as of 2026-07-10
- Revenue growth (YoY)+20.7% as of 2026-07-10
- Revenue CAGR (3y)+25.6% SEC XBRL
- Beta0.91 as of 2026-07-10
Key risks (from latest filing)
["WAKIX commercial success depends on market adoption for narcolepsy, a rare disease with limited patient population; regulatory approvals for pediatric indications and expanded indications like idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy are not assured.","Late-stage EPX-100 and EPX-200 clinical programs for rare epilepsy face development and regulatory risk; Phase 3 trial outcomes are uncertain, and commercial viability in these rare indications is unproven.","Dependency on exclusive license agreements with Bioprojet and Teijin Pharma; loss or modification of these agreements, licensing disputes, or failure to meet milestones could materially impact product portfolio and pipeline."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.